Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

Jong Hyun Jhee, Hye Young Kang, Meiyan Wu, Bo Young Nam, Tae Ik Chang, Su Young Jung, Seohyun Park, Hyoungnae Kim, Hae Ryong Yun, Youn Kyung Kee, Chang Yun Yoon, Jung Tak Park, TaeHyun Yoo, Shin-Wook Kang, SeungHyeok Han

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

Original languageEnglish
Pages (from-to)75-85
Number of pages11
JournalClinical Chemistry and Laboratory Medicine
Volume56
Issue number1
DOIs
Publication statusPublished - 2017 Nov 27

Fingerprint

Immunoglobulin A
Deterioration
Kidney
Glomerular Filtration Rate
Disease Progression
Biopsy
Biomarkers
Hazards
Confidence Intervals
Immunosorbents
Antigen-Antibody Complex
Proportional Hazards Models
Linear regression
Linear Models
Assays
Enzyme-Linked Immunosorbent Assay
Statistics
Association reactions

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Jhee, Jong Hyun ; Kang, Hye Young ; Wu, Meiyan ; Nam, Bo Young ; Chang, Tae Ik ; Jung, Su Young ; Park, Seohyun ; Kim, Hyoungnae ; Yun, Hae Ryong ; Kee, Youn Kyung ; Yoon, Chang Yun ; Park, Jung Tak ; Yoo, TaeHyun ; Kang, Shin-Wook ; Han, SeungHyeok. / Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy. In: Clinical Chemistry and Laboratory Medicine. 2017 ; Vol. 56, No. 1. pp. 75-85.
@article{ccf82c19b2c84d648ce590714f9ec880,
title = "Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy",
abstract = "Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30{\%} decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95{\%} confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95{\%} CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30{\%} decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.",
author = "Jhee, {Jong Hyun} and Kang, {Hye Young} and Meiyan Wu and Nam, {Bo Young} and Chang, {Tae Ik} and Jung, {Su Young} and Seohyun Park and Hyoungnae Kim and Yun, {Hae Ryong} and Kee, {Youn Kyung} and Yoon, {Chang Yun} and Park, {Jung Tak} and TaeHyun Yoo and Shin-Wook Kang and SeungHyeok Han",
year = "2017",
month = "11",
day = "27",
doi = "10.1515/cclm-2017-0090",
language = "English",
volume = "56",
pages = "75--85",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "1",

}

Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy. / Jhee, Jong Hyun; Kang, Hye Young; Wu, Meiyan; Nam, Bo Young; Chang, Tae Ik; Jung, Su Young; Park, Seohyun; Kim, Hyoungnae; Yun, Hae Ryong; Kee, Youn Kyung; Yoon, Chang Yun; Park, Jung Tak; Yoo, TaeHyun; Kang, Shin-Wook; Han, SeungHyeok.

In: Clinical Chemistry and Laboratory Medicine, Vol. 56, No. 1, 27.11.2017, p. 75-85.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy

AU - Jhee, Jong Hyun

AU - Kang, Hye Young

AU - Wu, Meiyan

AU - Nam, Bo Young

AU - Chang, Tae Ik

AU - Jung, Su Young

AU - Park, Seohyun

AU - Kim, Hyoungnae

AU - Yun, Hae Ryong

AU - Kee, Youn Kyung

AU - Yoon, Chang Yun

AU - Park, Jung Tak

AU - Yoo, TaeHyun

AU - Kang, Shin-Wook

AU - Han, SeungHyeok

PY - 2017/11/27

Y1 - 2017/11/27

N2 - Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

AB - Soluble CD89 (sCD89)-IgA complex plays a key role in the pathogenesis of IgA nephropathy (IgAN). However, there is a lack of evidence supporting this complex as a good biomarker for disease progression. This study aimed to evaluate the usefulness of sCD89-IgA complex for risk stratification of IgAN. A total of 326 patients with biopsy-proven IgAN were included. sCD89-IgA complex was measured by sandwich-enzyme-linked immunosorbent assay. The study endpoints were a 30% decline in estimated glomerular filtration rate (eGFR). sCD89-IgA complex levels were inversely and weakly associated with eGFR at the time of biopsy (r=-0.12, p=0.03). However, the significance between the two factors was lost in the multivariate linear regression after adjustment of clinical factors (β=0.35, p=0.75). In a multivariate Cox model, the highest (hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.35-1.61; p=0.45) and middle (HR, 0.93; 95% CI, 0.46-1.89; p=0.84) tertiles of sCD89-IgA complex levels were not associated with an increased risk of developing a 30% decrease in eGFR. Furthermore, the decline rates in eGFR did not differ between groups and C-statistics revealed that the sCD89-IgA complex were not superior to clinical factors in predicting disease progression. This study found no association between sCD89-IgA complex levels and disease progression in IgAN. Although sCD89 can contribute to the formation of immune complexes, our findings suggest that the sCD89-IgA level is not a good predictor of adverse outcomes and has limited clinical utility as a biomarker for risk stratification in IgAN.

UR - http://www.scopus.com/inward/record.url?scp=85037156566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037156566&partnerID=8YFLogxK

U2 - 10.1515/cclm-2017-0090

DO - 10.1515/cclm-2017-0090

M3 - Article

C2 - 28672768

AN - SCOPUS:85037156566

VL - 56

SP - 75

EP - 85

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 1

ER -